Investor's Business Daily on MSN
Stocks to watch: Vor Biopharma sees RS rating jump to 89
On Wednesday, Vor Biopharma VOR hit a noteworthy technical benchmark, seeing its Relative Strength (RS) Rating jump into the ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...
Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...
Vor Biopharma Inc. (VOR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VOR's 50-day simple moving average crossed above its ...
TipRanks on MSN
Vor Bio price target lowered to $40 from $43 at JPMorgan
JPMorgan analyst Anupam Rama lowered the firm’s price target on Vor Bio (VOR) to $40 from $43 and keeps an Overweight rating on the shares. The ...
New data from Vor Bio show that its hematopoietic stem cells have, so far, successfully engrafted in the first seven patients with relapsed or refractory acute myeloid leukemia and that the new cells ...
Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...
Vor Bio announces a $55.6 million PIPE to fund clinical trials and expects to report updated data in 2025. Vor Bio, a clinical-stage cell and genome engineering company, announced a securities ...
Vor Biopharma Inc. (NASDAQ:VOR) on Tuesday priced an underwritten public offering of 10 million shares at $10.00 per share. The gross proceeds from the offering are expected to be $100 million. In ...
Three years after Pulitzer Prize-winning writer and oncologist Dr. Siddhartha Mukherjee founded Vor Biopharma, the company finally has its first executive. Robert Ang, formerly the chief business ...
Vor Biopharma has done well to continue to advance its very own global phase 3 study using its dual BAFF/APRIL inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback